Taurine-diabetes interaction: From involvement to protection

Current Diabetes Reviews

Volumn 3, Issue 3, 2007, Pages 165-175

  Kim, Sung Jin ^a   Gupta, Ramesh C ^a,b   Lee, Hyeon Woo ^a  

^a Kyung Hee University   (South Korea)

^b NAGALAND UNIVERSITY   (India)

Author keywords

Taurine and diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANTIARRHYTHMIC AGENT; ASCORBIC ACID; ASTRAGALUS MEMBRANACEUS EXTRACT; FLAVONOID; FREE RADICAL; INSULIN; POTASSIUM; REACTIVE OXYGEN METABOLITE; STREPTOZOCIN; SULFONAMIDE; SULFONYLUREA; TAURINE; TAURINE DERIVATIVE; UBIDECARENONE;

ABDOMINAL DISEASE; AGING; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; EXERCISE; FETUS DEVELOPMENT; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; INFANT DISEASE; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; LIPID PEROXIDATION; LIVER INJURY; LIVER PROTECTION; NAUSEA; NONHUMAN; OSMOREGULATION; PATHOPHYSIOLOGY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; RADIATION INJURY; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM; VOMITING;

ANIMALS; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; INSULIN; LIVER DISEASES; MODELS, BIOLOGICAL; NERVOUS SYSTEM; PLATELET AGGREGATION; PREGNANCY; PREGNANCY IN DIABETICS; SULFONYLUREA COMPOUNDS; TAURINE; TISSUE DISTRIBUTION;

EID: 34547828050     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339907781368940     Document Type: Review

References (145)

1. Choughuley ASU, Lemmon RM. Production of cystic acid and Taurine and cyst amine under primitive earth conditions. Nature 1966;210:628.
2. Schadewaldt H. The history of diabetes mellitus in: VanEngelhardt D. Ed. Diabetes: its medicinal and cultural history. Berlin Springer 1987; 43-1.
3. Tiedmann F, Gamelin L. Einige neve Bestand theila der galle des ochsen. Ann Phys Chem 1827; 9: 326-7.
4. Jacobsen JG, Smith LH. Biochemistry and physiology of taurine and taurine derivatives. Physiol Rev 1968; 48: 424-511.
5. Kendler BS. Taurine; an overview of its role in preventive medicine. Prev Med 1989; 18: 79-100.
6. Hayes KC. 'Vitamin Like' molecule Taurine; Modern Nutrition in Health and Diseases Ed. Shiles and Young; Lea and Febiger, Pub. Philadelphia 1998; 464-70.
7. Kelly GS. Insulin resistance: lifestyle and nutritional interventions. Altern Med Rev 2000; 5: 109-32.
8. Savige GS. Candidate foods in the Asia-Pacific region for cardiovascular protection: fish, fruit and vegetables. Asia Pac J Clin Nutr 2001; 10: 134-7.
9. Sole MJ, Jeejeebhoy KN. Conditional nutritional requirements: therapeutic relevance to heart failure. Herz 2002; 27: 174-8.
10. Donadio G, Fromageot P. Influence exercise parlay taurine sur l'utilisation due glucose par le rat. Bull Soc Chim Biol (Paris) 1964; 46: 293-302.
11. Dokshina GA, Silaeva TIu, Lartsev EI. Insulin-like effects of taurine. Vopr Med Khim 1976; 22: 503-7.
12. Dokshina GA, Klimova AD, Jarcer EI, Jakovlev VG. Effect of taurine on insulin secretion by the isolated pancreatic tissue of intact and irradiated rats. Radiobiologiia 1976b; 16: 446-9.
13. Minor T, Yamaguchi T, Klauke H, Wingenfeld P, Michalk D, Isselhard W. Taurine reduces experimental liver injury after cold ischemic preservation and a period of rewarming prior to reperfusion. Adv Exp Med Biol 1996; 403: 157-61.
14. Hardikar AA, Risbud MV, Remacle C, Reusens B, Hoet JJ, Bhonde RR. Islet cryopresservation: improved recovery following taurine pretreatment. Cell Transplant 2001; 10: 247-53.
15. Falasca L, Tisone G, Palmieri G, et al. Protective role of taurour-sodeoxycholate during harvesting and cold storage of human liver: a pilot study in transplant recipients. Transplantation 2001; 71: 1268-76.
16. Aerts L, Van Assehe FA. Low taurine, gamma-aminobutyric acid and carnosine levels in plasma of diabetic pregnant rats: consequences for the offspring. J Perinat Med 2001; 29: 81-4.
17. McCarty MF. Exploiting complementary therapeutic strategies for the treatment of type II diabetes and prevention of its complications. Med Hypotheses 1997; 49: 143-52.
18. Gu W, Yang YZ, He MX. A study on combination therapy of Western and traditional Chinese medicine of acute viral myocarditis. Zhongguo Zhong Xi Yi Jie He Za Zhi 1996; 16: 713-6.
19. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129: 36-8.
20. Marx J. Unraveling the causes of diabetes. Scienee 2002; 296: 686-9.
21. Huxtable RJ, Sebring LA. Towards a unifying theory for the actions of taurine. Trends Pharmacol Sci 1986; 7: 481-5.
22. +/α-Taurine transporter International symposium; Taurine is 21st century Hawaii 2002; 20-3.
23. Poin PD, Kittleson MD, Rogers QR, Morris JG. Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy. Science 1987; 237: 764-8.
24. Sleeper MM, Henthorn PS, Vijayasarathy C, et al Dilated cardiomyopathy in juvenile Portuguese Water Dogs. J Vet Intern Med 2002; 16: 52-62.
25. Schaffer SW, Sayed-Mozaffari M, Kramer J, Tan BH. Effect of taurine depletion and treatment of cardiac contractility and metabolism. Prog Clin Biol Res 1985; 179: 167-75.
26. Mori M, Gahwiler BH, Gerber U. β alanine and taurine as endogenous agonists at glycine receptors in rat hippocampus in vitro. J Physiol 2002; 539: 191-200.
27. Lubec B, Ya-hua Z, Pertti S, Pentti T, Kitzmuller E, Lubec G. Distribution and disappearance of the radiolabeled carbon derived from L-arginine and taurine in the mouse. Life Sci 1997; 60: 2373-81.
28. Learn DB, Fried VA, Thomas EL. Taurine and hypotaurine content of human leukocytes. J Leukoc Biol 1990; 48: 174-82.
29. Paasonen MK, Solatunturi E, Nieminen ML. Blood Platelets: accumulation and release of taurine. Prog Clin Biol Res 1985; 179: 225-33.
30. Mansani FE, Cavatorta E, Ceruti M, Condemi V. Maternal and foetal aminoacidaemia and amino acids contents of amniotic fluid in normal, gestosic and diabetic pregnancy. Ateneo Parmense Acta Biomed 1975; 46: 545-69.
31. Martensson J, Hermansson G. Sulfur amino acid metabolism in juvenile-onset nonketotic and ketotic diabetic patients. Metabolism 1984; 33: 425-8.
32. Franconi F, Bennardini F, Mattana A, et al. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am J Clin Nutr 1995; 61: 1115-9.
33. Soltesz G, Schultz K, Mestyan J, Horvath I. Blood glucose and plasma amino acid concentration in infants of diabetic mothers. Pediatrics 1978; 61: 77-82.
34. De Luca G, Calpona PR, Caponetti A, et al. Preliminary report: Amino acid profile in platelets of diabetic patients. Metabolism 2001; 50: 739-41.
35. De Luca G, Calpona PR, Caponetti A, et al. Taurine and osmoregulation: platelet taurine content, uptake, and release in type 2 diabetic patients. Metabolism 2001; 50: 60-4.
36. Doksina GA, Klimova AD, Jarcev EI, Jakovlev VG. Inhibition of proteolytic ferments by taurine in radiation sickness. Radiobiol Radiother (Berl) 1975; 16: 339-45.
37. Abe M, Takahashi M, Takeuchi K, Fukuka M. Studies on the significance of taurine in radiation injury. Radiat Res 1968; 33: 563-73.
38. Bittner S, Win T, Gupta R. γ-L-glutamyltaurine. Amino Acids 2005; 28: 343-56.
39. Desai TK, Maliakkal J, Kinzie JL, Ehrinpreis MN, Luk GD, Cejka J. Taurine deficiency after intensive chemotherapy and/or radiation. Am J Clin Nutr 1992; 55: 708-11.
40. Ha H, Yu MR, Kim KH. Melatonin and taurine reduce early glomerulopathy in diabetic rats. Free Radic Biol Med 1999; 26: 944-50.
41. Stapleton PP, O'Flaherty L, Radmond HP, Bouchier-Hayes DJ. Host defense - a role for the amino acid taurine? JPEN J Parenter Enteral Nutr 1998; 22: 42-8.
42. Atlas M, Bahl JJ, Roeske W, Bressler R. In vitro osmoregulation of taurine in fetal mouse hearts. J Mol Cell Cardiol 1984; 16: 311-20.
43. Nieminen ML, Tuomisto L, Solatunturi E, Eriksson L, Paasonen MK. Taurine in the osmoregulation of Brattleboro rat. Life Sci 1988; 42: 2137-43.
44. Kannel WB, McGee DL. Diabetes and cardiovascular diseases. The Framingham study. JAMA 1979; 241: 2035-8.
45. Mahgoub MA, Abd-Elfattah AS. Diabetes mellitus and cardiac function. Mol Cell Biochem 1998; 180: 59-64.
46. Lampson WG, Kramer JH, Schaffer SW. Potentiation of the actions of insulin by taurine. Can J Physiol Pharmacol 1983; 61: 457-63.
47. Hamaguchi T, Azuma J, Schaffer S. Interaction of taurine with methionine: inhibition of myocardial phospholipid methyltransferase. J Cardiovasc Pharmacol 1991; 18: 224-30.
48. Holloway C, Kotsanas G, Wendt I. Acute effects of taurine on intracellular calcium in normal and diabetic cardiac myocytes. Pflugers Arch 1999; 438: 384-91.
49. Anuradha CV, Balakrishnan SD. Taurine attenuates hypertension and improves insulin sensitivity in fructose-fed rat, an animal model of insulin resistance. Can J Physiol Pharmacol 1999; 77: 749-54.
50. Mochizuki H, Takido J, Oda H, Yokogoshi H. Improving effect of dietary taurine on marked hypercholesterolemia induced by a high-cholesterol diet in streptozotocin-induced diabetic rats. Biosci Biotechnol Biochem 1999; 63: 1984-7.
51. Minor T, Yamaguchi T, Isselhard W. Effects of taurine on liver preservation in UW solution with consecutive ischemic rawarming in the isolated perfused rat liver. Transpl Int 1995; 8: 174-9.
52. Molloy AM, Tomkin GH. Altered bile in diabetic diarrhea. Br Med J 1978; 2: 1462-3.
53. Slivka Ola, Zelinskii BA, Zelinskii STs. Bile acids and the bile in diabetes mellitus. Probl Endokrinol (Mosk) 1979; 25: 16-9.
54. Meinders AE, Van Berge Henegouwen GP, Willekens FL, Schwerzel AL, Ruben A, Huybregts AW. Biliary lipid and bile acid composition in insuhn-dependent diabetes mellitus. Arguments for increased intestinal bacterial bile acid degradation. Dig Dis Sci 1981; 26: 402-8.
55. Villanueva GR, Herreros M, Perez-Barriocanal F, Bolanos JP, Bravo P, Marin JJ. Enhancement of bile acid-induced biliary lipid secretion by streptozotocin in rats: role of insulin deficiency. J Lab Clin Med 1990; 115: 441-8.
56. Villanueva GR, Herreros M, Perez-Barriocanal F, Fernandez E, Marin JJ. Effect of acute insulin administration on biliary lipid secretion by the diabetic rat. J Exp Pathol 1990; 71: 89-94.
57. Sugiyama K, Kushima Y, Muramatsu K. Effect of methionine, cysteine and taurine on plasma cholesterol level in rats fed a high cholesterol diet. Agric Biol Chem 1984; 48: 2897-9.
58. Murakami S, Kondo-Ohta Y, Tomisawa K. Improvement in cholesterol metabolism in mice given chronic treatment of taurine and fed a high-fat diet. Life Sci 1999; 64: 83-91.
59. Huxtable RJ. Physiological actions of taurine. Physiol. Rev 1992; 72: 101-63.
60. De Luca A, Pierno S, Tricarico D, et al. Taurine and skeletal muscle ion channels. Adv Exp Med Biol 2000; 483: 45-56.
61. Allo SN, Bagby L, Schaffer SW. Taurine depletion, a novel mechanism for cardioprotection from regional inchemia. Am J Physiol 1997; 273: H1956-61.
62. Chovan JP, Kulakowski EC, Benson BW, Schaffer SW. Taurine enhancement of calcium binding to rat heart sarcolemma. Biochim Biophys Acta 1979; 551: 129-36.
63. Chovan JP, Kulakowski EC, Sheakowski S, Schaffer SW. Calcium regulation by the low-affinity taurine binding sites of cardiac sarcolemma. Mol Pharmacol 1980; 17: 295-300.
64. Satoh H, Sperelakis N. Review of some actions of taurine on ion channels of cardiac muscle cells and others. Gen Pharmacol 1998; 30: 451-63.
65. Militante JD, Lombardini JB, Schaffer SW. The role of taurine in the pathogenesis of the cardiomyopathy of insulin-dependent diabetes mellitus. Cardiovasc Res 2000; 46: 393-402.
66. Schaffer SW, Punna S, Duan J, Harada H, Hamaguchi T, Azuma J. Mechanism underlying physiological modulation of myocardial contraction by taurine. Adv Exp Med Biol 1992; 315: 193-8.
67. Durlach J, Collery P. Magnesium and potassium in diabetes and carbohydrate metabolism. Review of the present status and recent results. Magnesium 1984; 3: 315-23.
68. Durlach J, Durlach V. Speculations on hormonal controls of magnesium homeostasis: a hypothesis. Magnesium 1984; 3: 109-31.
69. McCarty MF. Complementary vascular-protective actions of magnesium and taurine a rationale for magnesium taurate. Med Hypotheses 1996; 46: 89-100.
70. Durlach J, Pages N, Bac P, Bara M, Guiet-Bara A. Biorhythms and possible central regulation of magnesium status, phototherapy, dankness therapy and chromopathological forms of magnesium depletion. Magnes Res 2002; 15: 49-66.
71. Rassin DK, Sturman JA, Guall GE. Taurine and other free amino acids in milk of man and other mammals. Early Hum Dev 1978; 2: 1-13.
72. Zelikovic I, Chesney RW, Friedman AL, Ahlfors CE. Taurine depletion in very low birth weight infants receiving prolonged total parenteral nutrition: role of renal immaturity. J Pediatr 1990; 116: 301-6.
73. Dahri S, Snoeck A, Reusens-Billen B, Remacle C, Hoet JJ. Islet function in offspring of mothers on law-protein diet during gestation. Diabetes 1991; 40: 115-20.
74. Cherif H, Reusens B, Dahri S, Ramacle C, Hoet JJ. Stimulatory effects of taurine on insulin secretion by fetal islets cultured in vitro. J Endocrinal 1996; 151: 501-6.
75. Cherif H, Reusens B, Ahn MT, Hoet JJ, Remacle C. Effects of taurine on the insulin secretion of rat islets from dams fed a low-protein diet. J Endocrinol 1998; 159: 341-8.
76. Aerts L, Van Assche FA. Taurine and taurine-deficiency in the perinatal period. J Perinat Med 2002; 30: 281-6.
77. Maturo J, Kulakowski EC. Taurine binding to the purified insulin receptor. Biochem Pharmacol 1988; 37: 3755-60.
78. Ohkuma S, Tamura J, Kuriyama K. Insulin facilitates formation of taurine-conjugated bile acids-analysis using primary cultured hepatocytes. Jpn J Pharmacol 1984; 34: 475-9.
79. Salceda R. Insulin-stimulated tautine uptake in rat retina and retinal pigment epithelium. Neurochem Int 1999; 35: 301-6.
80. Guyot LL, Diaz FG, O'Regan MH, Song D, Phillis JW. The effect of topical insulin on the release of excitotoxic and other amino acids from the rat cerebral cortex during streptozotocin-induced hyperglacemic ischemia. Brain Res 2000; 872: 29-36.
81. Kjellman UW, Bjork K, Dahlin A, et al. Insulin(G1K) improves myocardial metabolism in patients during blood cardioplegia. Scand Cardiovasc J 2000; 34: 321-30.
82. Tokunaga H, Yoneda Y, Kuriyama K. Streptozotocin-induced elevation of pancreatic taurine content and suppressive effect of taurine on insulin secretion. Eur J Pharmacol 1983; 87: 237-43.
83. Nakaya Y, Minami A, Harada N, Sakamoto S, Niwa Y, Ohnaka M. Taurine improves insulin sensitivity in the Otsuka Long-Evens Tokushima Fatty rat, a model of spontaneous type 2 diabetes. Am J Clin Nutr 2000; 71: 54-8.
84. Bustamante J, Lobo MV, Alonso FJ, et al. An osmotic-sensitive taurine pool is localized in rat pancreatic islet cells containing glucagon and somastostation. Am J Physiol Endocrinol Metab 2001; 281: E1275-85.
85. Grant AC, Thomson J, Zammit VA, Shenman DB. Volume-sensitive amino acid efflux from a pancreatic β cell line. Mol Cell Endocrinol 2000; 162: 203-10.
86. Ackerman D, Heinsen HA. Umber die physiologists wiking des Aster a. ubins and underer, zurn Teil neu. dargestelter, schwefelhal tiger Gcraniclinderivate. Hoppe Seylers Z Physiol Chem 1936; 235: 115-21.
87. Hammes HP, Brownlee M. Advanced glycation end products and the pathogenesis of diabetic complications. In diabetes mellitus, Le Roith D, Taylor SI and Olefsky TM(Eds). Lippincott-Raven, Philadelphia 1996; 810-5.
88. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
89. Li H, Li JC, Rans SS, Du H, Gut P. Inhibiting effect of taurine on non enzymatic glucosylation of aortic collagen in diabetic ras. Chin Pharmacol Bull 1996; 12: 445-7.
90. Chang KJ. Effects of taurine and β-alanine on blood glucose and blood lipid concentrations in streptozotocin-induced diabetic rats. Kor J Nutr 1999; 32: 213-20.
91. Goodman HO, Shihabi ZK. Supplemental taurine in diabetic rats: effects on plasma glucose and triglycerides. Biochem Med Metab Biol 1990; 43: 1-9.
92. Chang KJ, Kwon W. Immunohistochemical. localization of insulin in pancreatic β cells of taurine-supplemented or taurine-depleted diabetic rats. Adv Exp Med Biol 2000; 483: 579-87.
93. Lim E, Park S, Kim H. Effect of taurine supplementation on the lipid peroxide formation and the activities of glutathione-related. enzymes in the liver and islet of typel and II diabetic model mice. Adv Exp Med Biol 1998; 442: 99-103.
94. Chang KJ. Effect of tsurine and β-alanine on morphological changes of pancreas in streptozotocin-induced rats. Adv Exp Med Biol 2000; 483: 571-7.
95. Clark CM Jr, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995; 332: 1210-7.
96. Stevens MJ, Lattimer SA, Kamijo M, Van Huysen C, Sims, AA, Greene DA. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropthy in the rat. Diabetologia 1993; 36: 608-14.
97. Trachtman H, Futterweit S, Sturman JA. Cerebral taurine transport is increased during streptozocin-induced diabetes in rats. Diabetes 1992; 41: 1130-40.
98. Obrosova IG, Fathallah, Stevens MI. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp Neurol 2001; 172: 211-19.
99. Pop-Busui R, Sullivan KA, Van Huysen C, et al. Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular and functional deficits. Exp Neurol 2001; 168: 259-72.
100. Pop-Busui R, Marinescu U, Van Huysen C, et al. Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acety1-L-carnitine administration. Diabetes 2002; 51: 2619-28.
101. Bergstrom J, Alvestrand A, Furst P, Lindholm B. Sulphur amino acids in plasma and muscle in patients with chronic renal failure: evidence for taurine depletion. J Intern Mod 1989; 226: 189-94.
102. Suliman ME, Anderstam B, Bergstrom J. Evidence of taurine depletion and accumulation of eysteinesulfinic acid in chronic dialysis patients. Kidney Int 1996; 50: 1713-7.
103. Suliman ME, Anderstain B, Lindholm B, Bergstrom J. Total, free, and protein-bound sulphur amino acids in uremia patients. Nephrol Dial Transplant 1997; 12: 2332-8.
104. Suliman ME, Qureshi AR, Barany P, et al. Hyperhomocysteinemia, nutritional status and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57: 1727-35.
105. Nakamura T, Ushiyama C, Suzuki S, et al. Effects of taurine and vitamin E on microalbuminuria, plasma metalloproteinase-9, and serum type IV collagen concentrations in patients with diabetic nephropathy. Nephron 1999; 83: 361-2.
106. Alvestrand A, Furst P, Bergstrom J. Plasma and muscle free amino acids in uremia: influence of nutrition with amino acids. Clin Nephrol 1982; 18: 297-305.
107. Sankarasubbaiyan S, Cooper C, Heilig CW. Identification of a novel form of renal glucosuria with overexcretion of arginine, carnosine, and taurine. Am J Kidney Dis 2001; 37: 1039-43.
108. Suliman ME, Stenvinkel P, Heimburger O, Barany P, Lindholm B, Bergstrom J. Plasma sulfur amino acids in relation to cardiovascular diseases, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kideney Dis 2002; 40: 486-8.
109. Reibel DK, Shaffer JE, Kocsis JJ, Neely JR. Changes in taurine content in heart and other organs of.diabetic rats. J Mol Cell Cardiol 1979; 11: 827-30.
110. Kinne RKH, Ruhfus B, Boese SH, Wehner F. Organic osmolytes and cell volume regulation: taurine transporters in liver and kidney. Nova Acta Leopold 1998; 18: 243-52.
111. Trachtman H, Lu P, Sturman JA. Immunohistochemical localization of taurine in rat renal tissue: studies in experimental diseases states. J Histochem Cytochem 1993; 41: 1209-16.
112. Park SH, Choi HJ, Lee JH, Woo CH, Kim JH, Han HJ. High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress and TGF-β1. Kidney Int 2001; 59: 1695-705.
113. Malone JI, Lowitt S, Cook WR. Nonosmotic; diabetic cataracts. Pediatr Res 1990; 27: 293-6.
114. Kilic F, Bhardwaj R, Caulfeild J, Trevithick JR. Modeling cortical cataractogenesis 22: is in vitro reduction of damage in model diabetic rat cataract by taurine due to its antioxidant activity. Exp Eye Res 1999; 69: 291-300.
115. Mitton KP, Linklater HA, Dzialoszynski T, Sanford SE, Starkey K, Trevithick JR. Modeling cortical cataractogenesis 21: in diabetic rat lenses taurine supplementation partially reduces damage resulting from osmotic compensation lending to osmolyte loss and antioxidant depletion. Exp Eye Res 1999; 69: 279-89.
116. Obrosova IG, Stevens MJ. Effect of dietary taurine supplementation on GSH and NAD(P)-redox status, lipid peroxidation and energy metabolism in diabetic precataractous lens. Invest Opthalmol Vis Sci 1999; 40: 680-8.
117. Kumar JS, Menon VP. Changes in levels of lipid peroxides and activity of superoxide dismutase ind catalase in diabetes associated with myocardial infarction. Indian J Exp Biol 1992; 30: 122-7.
118. Wright CE, Tallan HH, Lin YY, Gaull GE. Taurine: biological update. Annu Rev Biochem 1986; 55: 427-53.
119. Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87: 1123-32.
120. Azuma M, Takahashi K, Fukuda T, et al. Taurine attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac myocytes. Eur J Pharmacol 2000; 403: 181-8.
121. Nieminen ML, Tuomisto L, Solatunturi E. Platelet taurine concentration and uptake in the Brattleboro diabetes insipidus rat. Acta Med Okayama 1996; 50: 203-10.
122. Hayes KC, Pronczuk A, Addesa AF, Stephan ZF. Taurine modulates platelet aggregation in cats and humans. Am J Clin Nutr 1989; 49: 1211-16.
123. Charach G, Rabinovich PD, Konikoff FM, Grosskopf I, Weintraub MS, Gilat T. Decreased fecal bile acid output in patients with coronary arteriosclerosis. J Med 1998; 29: 125-36.
124. Mochizuki H, Oda H, Yokogoshi H. Increasing effect of dietary taurine on the serum HDL-cholesterol concentration in rats. Biosci Biotechnol Biochem 1998; 62: 578-9.
125. Kamata K, Sugiura M, Kojima S, Kasuya Y. Restoration of endothelium-dependent relaxation in both hypercholesterolemia and diabetes by chronic taurine. Eur J Pharmacol 1996; 303: 47-53.
126. Szabo A, Kenesei E, Milteny IM, Korner A, Szucs L, Nagy I. Follow-up of blood and urinary amino acid concentrations in diabetic ketoacidosis in children. Orv Hetil 1990; 131: 615-9.
127. Jansson T, Ekstrand Y, Bjorn C, Wennergren M, Powell TL. Alterations in the activity of placental amino acid transporters in pregnancies complicated by diabetes. Diabetes 2002; 51: 2214-9.
128. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992; 35: 595-601.
129. Reusens B, Remacle C. Intergenerational effect of an adverse intrauterine environment on perturbation of glucose metabolism. Twin Res 2001; 4: 406-11.
130. Ford GA, Preece JD, Davies IH, Wilkinson SP. Use of the SeHCAT test in the investigation of diarrhea. Postgrad Med J 1992; 68: 272-6.
131. Wingenfeld P, Gehrmann U, Strubind S, Minor T, Isselhard W, Michalk DV. Long-lasting hypoxic preservation of porcine kidney cells. Beneficial effect of taurine on viability and metabolism in a simplified transplantation model. Adv Exp Med Biol 1996; 403: 203-12.
132. Wu QD, Wang JH, Fennessy F, Redmond HP, Bouchier-Hayes D. Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis. Am J Physiol 1999; 277: C1229-38.
133. Ikeda M, Nanri H, Himeno E. Health and excrete: effects of exercise on high blood pressure. J UOEH 1993; 15: 227-36.
134. Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 1999; 277: E1130-41.
135. Lehmann R, Vokac A, Niedermann K, Agosti K, Spinas GA. Loss of abdominal fat and improvement of the cardiovascular risk profile by regular moderate exercise training in patients with NIDDM. Diabetologia 1995; 38: 1313-9.
136. Arakawa K. Exercise, a measure to lower blood pressure and reduce other risks. Clin Exp Hypertens 1999; 21: 797-803.
137. Barthel T, Mechau D, Wehr T, Schnittker R, Liesen H, Weiss M. Readiness potential in different states of physical activation and after ingestion of taurine and/or caffeine containing drinks. Amino Acids 2001; 20: 63-73.
138. Forslund AH, Hambraeus L, van Beurdem H, et al. Inverse relationship between protein intake and plasma free amino acids in healthy men at physical exercise. Am J Physiol Endocrinol Metab 2000; 278: E857-67.
139. Dawson R Jr, Liu S, Eppler B, Patterson T. Effects of dietary taurine supplementation or deprivation in aged male Fischer 344 rats. Mech Ageing Dev 1999; 107: 73-91.
140. Dawson R Jr. Taurine in aging and models of neurodegeneration. Taurine in 21st century, international symposium, Hawaii, 2002; 20-23: 36.
141. Schaffer SW, Azuma J, Madurra JD. Mechanism underlying taurine mediated alterations in membrane function. Amino Acids 1995; 8: 231-46.
142. Shindo S, Huxtable RJ. Interaction of taurine with phospholipid vesicles. Sulfur Amino Acids 1987; 10: 127-32.
143. Chauncey KB, Tenner TE Jr, Lombardini JB, et al. The effect of taurine supplementation on patients with Type 2 diabetes mellitus. international symposium: Taurine in the 21st century, Hawaii, 2002; 20-23: 52.
144. Huxtable RJ, Nakagawa K. The Anticonvulsant action of two taurine derivatives in genetic and chemically induced seizures. Prog Clin Biol Res 1985; 179: 435-48.
145. Gupta RC, Win T, Bittner S. Taurine analogues; a new class of therapeutics: retrospect and prospects. Curr Med Chem 2005; 12: 2021-39.